Jamerson B D, Dukes G E, Brouwer K L, Donn K H, Messenheimer J A, Powell J R
School of Pharmacy, University of North Carolina at Chapel Hill 27599-7360.
Pharmacotherapy. 1994 Jan-Feb;14(1):47-52. doi: 10.1002/j.1875-9114.1994.tb02788.x.
To compare the frequency, severity, and time course of venous irritation after administration of a single intravenous dose of phenytoin with an equimolar dose of fosphenytoin, a water-soluble phenytoin prodrug.
Randomized, double-blind, two-period, crossover study.
University hospital clinical research unit.
Twelve healthy volunteers within 15% of ideal body weight and with no clinically significant abnormalities on physical examination, medical history, or laboratory assessment.
Volunteers randomly received a 30-minute infusion of phenytoin sodium 250 mg (250 mg/5 ml) or an equimolar dose of fosphenytoin 375 mg (375 mg/5 ml). Subjects returned for the crossover treatment 14-21 days later.
Subjects assessed venous irritation (pain, burning, itching), and investigators evaluated phlebitis (erythema, swelling, tenderness), induration, exudation, and cording. Phenytoin was associated with a significantly higher degree of pain at the infusion site in all subjects and a significant degree of phlebitis in eight subjects (p < 0.05); cording occurred in six subjects. The time course of phenytoin-induced phlebitis was bimodal. Erythema and tenderness were prominent at the end of the infusion and again at 24 hours. Cording was first noted between 24 hours and 1 week after infusion. In contrast, fosphenytoin was associated with mild pain in two subjects, one incident of phlebitis, and no erythema or cording.
Fosphenytoin administration resulted in significantly less venous irritation and phlebitis compared with an equimolar dose of phenytoin. The clinical use of this water-soluble phenytoin prodrug should minimize the frequency and severity of infusion-site reactions and should allow convenient, rapid, intravenous administration of drug, undiluted or admixed with intravenous solutions.
比较单次静脉注射苯妥英钠与等摩尔剂量的磷苯妥英(一种水溶性苯妥英前体药物)后静脉刺激的频率、严重程度和时间进程。
随机、双盲、两阶段、交叉研究。
大学医院临床研究单位。
12名健康志愿者,体重在理想体重的15%以内,体格检查、病史或实验室评估均无临床显著异常。
志愿者随机接受30分钟输注250mg苯妥英钠(250mg/5ml)或等摩尔剂量的375mg磷苯妥英(375mg/5ml)。受试者在14 - 21天后返回接受交叉治疗。
受试者评估静脉刺激(疼痛、烧灼感、瘙痒),研究者评估静脉炎(红斑、肿胀、压痛)、硬结、渗出和条索形成。苯妥英钠在所有受试者中均与输注部位显著更高程度的疼痛相关,在8名受试者中出现显著程度的静脉炎(p < 0.05);6名受试者出现条索形成。苯妥英钠所致静脉炎的时间进程呈双峰型。红斑和压痛在输注结束时及24小时时再次出现。条索形成在输注后24小时至1周之间首次出现。相比之下,磷苯妥英钠在2名受试者中引起轻度疼痛,1例静脉炎,无红斑或条索形成。
与等摩尔剂量的苯妥英钠相比,磷苯妥英钠给药导致的静脉刺激和静脉炎明显更少。这种水溶性苯妥英前体药物的临床应用应能将输注部位反应的频率和严重程度降至最低,并应允许方便、快速地静脉给药药物,无需稀释或与静脉溶液混合。